|

Mental Stress Reactivity in Women With CMD

RECRUITINGN/ASponsored by Emory University
Actively Recruiting
PhaseN/A
SponsorEmory University
Started2022-07-19
Est. completion2026-09-30
Eligibility
Age45 Years+
SexFEMALE
Healthy vol.Accepted
Locations4 sites

Summary

Coronary Microvascular Dysfunction (CMD) occurs when there are problems in the small blood vessels/arteries of the heart, resulting in persistent chest pain that affects women. There are an estimated 3 million women in the US with CMD and about 100,000 new cases annually. This research will investigate whether the stress response physiology and autonomic function in response to mental stress are different in women with CMD compared to other groups. The autonomic nervous system (ANS) controls normally involuntary activities, such as heart rate, respiration (breathing), body temperature, blood pressure, and urinary function. This study will also examine how chronic and daily life mental stress affects the heart and blood vessels. Participants from this study will be recruited mainly from Emory Healthcare-associated hospitals, the Emory Heart Disease Center for Prevention, and Emory Healthcare outpatient cardiology clinics. Participants will have physical exams, blood tests, stress tests, exercise tests, surveys, questionnaires, and images taken of their hearts and blood vessels. They will be asked to take home devices to monitor their autonomic function, sleep, and track their mood, stress level, and symptoms for one week. Data and specimens will be saved for future research.

Eligibility

Age: 45 Years+Sex: FEMALEHealthy volunteers accepted
CMD Group

Inclusion Criteria:

* Symptomatic postmenopausal women with chest pain
* age≥45 years old
* willing to undergo cardiac MIBG scan
* willing to undergo mental stress testing
* competent to give informed consent

Exclusion Criteria:

* Significant epicardial stenosis (defined by coronary stenosis ≥ 70% in any epicardial coronary artery or hemodynamically significant stenosis determined by fractional flow reserve)
* Left ventricular systolic dysfunction (ejection fraction ≤ 50%)
* Heart failure with a preserved ejection fraction
* Significant anemia or blood dyscrasia
* Severe uncontrolled hypertension \>180/100
* Unable to lie flat for mental stress testing
* Pre-menopausal
* Pregnant
* Pericarditis/myocarditis
* History of percutaneous coronary intervention
* Coronary artery bypass grafting
* Acute myocardial infarction/acute coronary syndrome/unstable angina within 1 month
* Significant valvular disease, including aortic or mitral stenosis
* Sinus node dysfunction/pacemaker, 2nd or 3rd-degree atrioventricular block
* Severe lung, renal, liver, or psychiatric illness
* Current neoplasm
* History of substance abuse
* Acute illness such as infection in the previous 4 weeks
* Life-expectancy less than 2 years
* Unable to safely withdraw medications for mental stress testing
* Significant psychiatric illness that precludes safe participation in the study
* Conditions that preclude accurate or safe testing and patient refusal
* Unable to consent

Obstructive CAD (oCAD) Group

Inclusion Criteria:

* Symptomatic postmenopausal women with chest pain who have obstructive CAD in at least one epicardial coronary artery
* willing to undergo cardiac MIBG scan
* willing to undergo mental stress testing
* competent to give informed consent

Exclusion Criteria:

* Significant epicardial stenosis (defined by coronary stenosis ≥ 70% in any epicardial coronary artery or hemodynamically significant stenosis determined by fractional flow reserve)
* Left ventricular systolic dysfunction (ejection fraction ≤ 50%)
* Heart failure with a preserved ejection fraction
* Significant anemia or blood dyscrasia
* Severe uncontrolled hypertension \>180/100
* Unable to lie flat for mental stress testing
* Pre-menopausal
* Pregnant
* Pericarditis/myocarditis
* History of percutaneous coronary intervention
* Coronary artery bypass grafting
* Acute myocardial infarction/acute coronary syndrome/unstable angina within 1 month
* Significant valvular disease, including aortic or mitral stenosis
* Sinus node dysfunction/pacemaker, 2nd or 3rd-degree atrioventricular block
* Severe lung, renal, liver, or psychiatric illness
* Current neoplasm
* History of substance abuse
* Acute illness such as infection in the previous 4 weeks
* Life expectancy is less than 2 years
* Unable to safely withdraw medications for mental stress testing
* Significant psychiatric illness that precludes safe participation in the study
* Conditions that preclude accurate or safe testing and patient refusal
* Unable to consent

Asymptomatic Control Group

Inclusion Criteria:

* Asymptomatic postmenopausal women, age ≥ 45 years old
* Healthy volunteer with no cardiac risk factors
* No history or diagnosis of heart disease
* Not on any cardiac medications
* Normal maximal exercise treadmill stress testing (ETT)
* Fully understanding and willing to undergo mental stress testing
* Willing to sign the informed consent

Exclusion Criteria:

* Significant epicardial stenosis (defined by coronary stenosis ≥ 70% in any epicardial coronary artery or hemodynamically significant stenosis determined by fractional flow reserve)
* Left ventricular systolic dysfunction (ejection fraction ≤ 50%)
* Heart failure with a preserved ejection fraction
* Significant anemia or blood dyscrasia
* Severe uncontrolled hypertension \>180/100
* Unable to lie flat for mental stress testing
* Pre-menopausal
* Pregnant
* Pericarditis/myocarditis
* History of percutaneous coronary intervention
* Coronary artery bypass grafting
* Acute myocardial infarction/acute coronary syndrome/unstable angina within 1 month
* Significant valvular disease, including aortic or mitral stenosis
* Sinus node dysfunction/pacemaker, 2nd or 3rd-degree atrioventricular block
* Severe lung, renal, liver, or psychiatric illness
* Current neoplasm
* History of substance abuse
* Acute illness such as infection in the previous 4 weeks
* Life expectancy is less than 2 years
* Unable to safely withdraw medications for mental stress testing
* Significant psychiatric illness that precludes safe participation in the study
* Orthopedic limitation that will prevent ETT
* LDL \>120 mg/dL
* Fasting blood glucose \>95 mg/dL
* Hypertension, defined as resting BP \>120/80
* Diabetes
* Hyperlipidemia
* Smoking
* Conditions that preclude accurate or safe testing and patient refusal
* Unable to consent

Conditions2

Heart DiseasePost-menopause

Locations4 sites

Emory Hospital Midtown
Atlanta, Georgia, 30308
Emory Saint Joseph's Hospital
Atlanta, Georgia, 30308
Emory Clinic
Atlanta, Georgia, 30322
Emory Hospital
Atlanta, Georgia, 30322

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.